Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites

• Status: Completed
• Trial end date: 2020-04-30
• Target enrollment: 0
• Participant gender: All

Summary

This work aimed to evaluate and compare the impact of adding hypertonic saline solution (HSS) infusion and/or etilefrine to oral diuretics therapy on clinical outcomes, renal and systemic hemodynamics, metabolic and inflammatory pathways by estimating the changes in selected biological markers in cirrhotic patients with ascites. Also, the trial aims to assess the safety and tolerability of such treatment regimens.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hala Abd EL-Tawab Ibrahim Radwan
• Treatments: Diuretics; Etilefrine; Furosemide; Pharmaceutical Solutions; Spironolactone

Criteria

Inclusion Criteria:

• All cirrhotic patients with ascites grade I- III.

• Patients ages from 25 -65 years.

Exclusion Criteria:

• Non-cirrhotic ascites.

• Congestive heart failure.

• Acute renal failure.

• Hepatocellular carcinoma.

• All Cancer types.

• Arterial hypertension.

• Acute infection.